Variational AI, developer of state-of-the-art generative AI technology to redefine the economics of drug development by accelerating the discovery of novel and ...

VANCOUVER, British Columbia--(BUSINESS WIRE)--Variational AI, the company behind Enki™, an advanced foundation model for small molecule drug discovery, today ...

Merck & Co. has doubled down on its partnership with Variational AI, striking a deal worth up to $349 million to collaborate on small molecule candidates against two targets. Variational disclosed a ...

Vancouver firm's AI platform will generate chemical compounds based on Merck’s therapeutic targets. A Vancouver startup using artificial intelligence (AI) to discover new drugs has struck a deal with ...

“We are pleased to announce Merck as an early-access user of our Enki™ Platform,” said Handol Kim, CEO, Variational AI. “Merck will evaluate Enki’s ability to generate novel small molecules on targets ...

Quantum computing presents opportunities in strategic planning and discovery through complex simulations, but also risks in data security via Shor’s algorithm. Businesses must prepare now to leverage ...